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observational cohortsIn 2000, only 2% of people living with HIV worldwide
were receiving life-saving antiretroviral therapy (ART).
Of these, less than 1% (11 000 of the 700 000 on ART)
lived in sub-Saharan Africa. By 2014, the percentage of
HIV-positive people receiving ART had risen to 40%,
representing almost 15 million people, with over two-
thirds (10.7 million) living in sub-Saharan Africa [1].
The successful scale up of ART over the last 15 years is
therefore largely an African success story. The evaluation
of Botswana’s public ART programme published in this
issue of AIDS provides a national example of the progress
made by almost all high HIV-burden countries in Africa
[2]. By the end of 2014, the national programme had
started almost 250 000 people on ART, from 3500 in
2002. Adult mortality during the first year on ART
declined from 7 to 2%, likely as a result of the
progressively earlier access to treatment, with average
CD4þ at start of ART rising from 88 cells/ml in 2002 to
258 cells/ml in 2013.
Some uncertainty about the true impact on mortality,
however, remains in Botswana and elsewhere. Deaths
among patients lost to follow-up were not ascertained and
rates will underestimate the mortality experienced by all
patients who started ART. Also, some of the decline in
mortality observed in Botswana [2] may be because of
declining ascertainment of mortality as the programme Copyright © 2016 Wolters Kluwe
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0269-9370 Copyright Q 2016 Wolters Kexpanded and retention in care got worse. Finally, the
inverse probability of censoring weights implemented in
the regression analysis [2] may perform poorly in the
absence of additional information on mortality in patients
lost to follow-up [3].
Reported factors for adult mortality in the Botswana
national programme [2] are consistent with other reports,
and include severe immune deficiency at start of ART [4],
male sex [5,6], older age [7], and receipt of suboptimal
(i.e. less potent/tolerable) ART regimens [8,9]. Although
most countries are now providing tenofovir-based
regimens as standard first-line ART, too little progress
has been made in identifying and implementing
interventions to reduce mortality associated with these
and other well established risk factors. There is a need to
move beyond descriptive epidemiology and identify
interventions to help enrol people into care earlier in their
disease progression, engage and support men, and
respond to the multiple morbidities faced by older
people living with HIV [10–12].
The lessons from Botswana’s HIV programme are
indicative of both the successes made in increasing access
to treatment and reducing mortality – ART scale up is
estimated to have averted almost 8 million deaths
worldwide [1] – and the challenges that need to be
overcome to further reduce HIV-associated mortality.r Health, Inc. All rights reserved.
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522 AIDS 2016, Vol 30 No 3To further reduce mortality and severe morbidity, the first
priority for HIV programmes is to identify HIV-positive
individuals earlier in their disease progression and start
ARTas soon as possible following diagnosis. A succession
of international and national guideline changes have
recommended earlier initiation of ART [13], and this has
been associated with an increase in the average CD4þ cell
count at start of ART [14]. In October 2015 the World
Health Organization released guidance recommending
that all HIV-positive individuals should receive ART
irrespective of CD4þ cell count [15]. This follows the
results of the START [16] and TEMPRANO [17] trials
to recommend immediate initiation of ART independent
of clinical or immunological status. However, while the
average CD4þ cell count at the start of ART has increased
over the years, still around a quarter of people continue to
start ART very late, at CD4þ less than 100 cells/ml [3,18],
which in the Botswana study increased the odds of death
by 1.9 times. Late diagnosis remains part of the problem –
around a third of HIV-positive hospitalized individuals
only learn of their status at the time of hospitalization
because of a severe illness event [19] – indicating that
changes to ART initiation thresholds in the clinic will not
completely overcome the challenge of late presentation
to care, and innovative testing approaches including
community and self-testing need to be brought to scale
[20].
The second priority is to establish clinical and operational
mechanisms to improve outcomes for patients who present
to care with advanced disease in spite of attempts to identify
patients earlier and link them to care. Analyses of mortality
on ART miss the very high mortality in patients eligible for
ART who never get to start ART [21,22].
The third priority in reducing mortality among people on
ART is to address the important number of patients who
disengage from care following ART initiation [23], which
is of increasing importance as the fraction of the HIV
population on ART continuously increases. Studies
suggest that around a third of patients who are lost to
care are subsequently found to have died [24], with
substantial regional variation which is partly explained by
differences in programme resources invested in patient
tracing and individual opportunities to reengage in care.
Population-based studies of HIV-associated mortality
demonstrate that an increasing proportion of HIV-
associated deaths are in patients who had previously been
on ART [21].
These latter two challenges – reducing mortality among
late presenters and keeping those on ART in long-term
care – have led to calls for services to adapt service
intensity according to the specific needs of different
groups of individuals across the cascade [25]. With a
global policy shift towards starting ART immediately,
improving coverage of HIV testing, and providing
adapted care are the key ART service delivery priorities Copyright © 2016 Wolters Kluwer Hfor the coming years to address the specific challenges of
different patient populations – late presenters, those
disengaging from care, men and elderly populations as
highlighted by this report, but also children [26],
adolescents [27], and key populations [28], all of whom
continue to be underserved by the broader HIV response.Acknowledgements
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